NEW YORK (GenomeWeb News) – Leica Biosystems and Synthon Biopharmaceuticals announced today a collaboration to develop and commercialize companion diagnostics for drugs aimed at treating solid tumors.

The firms will develop companion diagnostics based on Leica's Bond automated advanced staining systems for use with Synthon Bio's antibody-drug conjugates for treating solid tumors. The companies said the deal provides a framework for further collaborations but provided no details about the terms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.